| SPE | septic pulmonary edema; serum protein electrolytes; serum protein electrophoresis; streptococcal pyr... |
|---|---|
| SPI | Self-Perception Inventory; serum precipitable iodine; serum protein index; Shipley Personal Inventor... |
| RS | radioscaphoid; random sample; rating schedule; Raynaud syndrome; recipient's serum; rectal sinus; re... |
| SPLV | serum parvovirus-like virus |
| RS virus | Respiratory Synthitial virus |
| hepatitis b, chronic | An inflammatory disease of the liver caused by hepatitis b virus and lasting six months or more. (12 Dec 1998) |
|---|---|
| hepatitis B core antigen | <virology> (HBcAb, HBcAg), the antigen found in the core of the Dane particle (which is the complete virus) and also in hepatocyte nuclei in hepatitis B infections. (05 Mar 2000) |
| hepatitis B e antigen | (HBeAb, HBe, HBeAg), an antigen, or group of antigen's, associated with hepatitis B infection and distinct from the surface antigen (HBsAg) and the core antigen (HBcAg); it is associated with the viral nucleocapsid. Its presence indicates that the virus is replicating and the individual is potentially infectious. (05 Mar 2000) |
| hepatitis b e antigens | A closely related group of antigens found in the plasma only during the infective phase of hepatitis b or in virulent chronic hepatitis b, probably indicating active virus replication; there are three subtypes which may exist in a complex with immunoglobulins g. (12 Dec 1998) |
| hepatitis b immunization | Hepatits B (hep B) vaccine gives prolonged protection, but 3 shots over a half year are usually required. In the u.s., all infants receive hep b vaccine. Two vaccines (engerix-b, and recombivax-hb) are available in the us. The first dose of hep b vaccine is frequently given while the newborn is in the hospital or at the first doctor visit following birth. The second dose is given about 30 days after the initial dose. A booster dose is performed approximately six months later. Babies born to mothers testing positive for hep b receive, in addition, hbig (hep b immune globulin) for prompt protection. Older children (11-12 years) are advised to receive a hep b booster as are adults in high-risk situations including healthcare workers, dentists, intimate and household contacts of patients with chronic hep b infection, male homosexuals, individuals with multiple sexual partners, dialysis patients, iv drug users, and recipients of repeated transfusions. Healthcare workers accidentally exposed to materials infected with hep b (such as needle sticks), and individuals with known sexual contact with hep b patients are usually given both hbig and vaccine to provide immediate and long term protection. (12 Dec 1998) |
| hepatitis B surface antigen | <virology> A serologic marker on the surface of the hepatitis B virus. The body will normally produce antibodies to hepatitis B surface antigen as part of the normal immune response to infection. It is the presence of antibodies to the hepatitis B surface antigen that are detected in a positive hepatitis B blood test. (27 Sep 1997) |
| hepatitis b surface antigens | Those hepatitis b antigens found on the surface of the dane particle and on the 20 nm spherical and tubular particles. Several subspecificities of the surface antigen are known. These were formerly called the Australia antigen. (12 Dec 1998) |
| hepatitis B vaccine | <virology> An injectable vaccine, given in three boosters, which offers protection from infection with hepatitis B. (27 Sep 1997) |
| hepatitis b vaccines | Vaccines or candidate vaccines containing inactivated hepatitis b or some of its component antigens and designed to prevent hepatitis b. Some vaccines may be recombinantly produced. (12 Dec 1998) |
| hepatitis C | <virology> A form of viral hepatitis, previously referred to as nonA nonB hepatitis, is the most common form of blood transfusion acquired hepatitis. Transmission through sexual contact is considered rare. Risk factors include recent blood transfusion, IV drug abuse or occupational exposure to blood products. There is no specific treatment. There is a test for hepatitis C antibody which indicates prior exposure. Unlike hepatitis b there is no marker yet identifiable for those who suffer from chronic hepatitis C. (27 Sep 1997) |
| hepatitis c antibodies | Antibodies to the hepatitis c antigens including antibodies to envelope, core, and non-structural proteins. (12 Dec 1998) |
| hepatitis c antigens | Antigens of the virions of hepatitis c-like viruses, their surface, core, or other associated antigens. (12 Dec 1998) |
| hepatitis c, chronic | An inflammatory disease of the liver caused by hepatitis c virus lasting six months or more. (12 Dec 1998) |
| hepatitis, chronic | A collective term for a clinical and pathological syndrome which has several causes and is characterised by varying degrees of hepatocellular necrosis and inflammation. Specific forms of chronic hepatitis include autoimmune hepatitis (hepatitis, autoimmune), chronic hepatitis b (hepatitis b, chronic), chronic hepatitis c (hepatitis c, chronic), chronic hepatitis d (hepatitis d, chronic), indeterminate chronic viral hepatitis, cryptogenic chronic hepatitis and drug-related chronic hepatitis (hepatitis, chronic, drug-induced). (12 Dec 1998) |
| hepatitis, chronic, drug-induced | An inflammatory disease of the liver, lasting six months or more, and caused by an adverse drug effect. The adverse effect may result from a direct toxic effect of a drug or metabolite, or an idiosyncratic response to a drug or metabolite. The clinical and histological changes can mimic viral or autoimmune hepatitis. (12 Dec 1998) |